# US 2021/0231655 A1 · Method, System, and Program for Supplying Immunodynamics-Related Information

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0231655 A1
- Document ID: US20210231655A1
- Status: Published application
- Kind: A1
- Application number: 16/958,167
- Filed: 2018-12-25
- Published: 2021-07-29
- Earliest claimed: 2017-12-26
- Inventors: Tamio Yamauchi
- Web page: https://patentgrep.com/patent/US20210231655A1

## CPC

- G01N 33/557: using kinetic measurement, i.e. time rate of progress of an antigen-antibody interaction
- G01N 33/5047: {Cells of the immune system}
- G01N 33/56972: {White blood cells}
- G16B 5/00: ICT specially adapted for modelling or simulations in systems biology, e.g. gene-regulatory networks, protein interaction networks or metabolic networks
- G16B 45/00: ICT specially adapted for bioinformatics-related data visualisation, e.g. displaying of maps or networks
- G16B 50/30: Data warehousing; Computing architectures
- G16H 20/10: relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H 20/40: relating to mechanical, radiation or invasive therapies, e.g. surgery, laser therapy, dialysis or acupuncture
- G16H 50/20: for computer-aided diagnosis, e.g. based on medical expert systems
- G16H 50/30: for calculating health indices; for individual health risk assessment
- G16H 50/70: for mining of medical data, e.g. analysing previous cases of other patients
- Y02A 90/10: Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- G16H: HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

The present invention addresses the problem of providing a method, a system, and a program for supplying immunodynamics-related information that is used in order to readily understand the immunodynamics of the cell-mediated immunity of a subject and to determine a method for treating or a method for preventing a disease and/or a symptom in a subject. This method, system and program supply immunodynamics-related information that is used in order to determine a method for treating or a method for preventing a disease and/or a symptom in a subject by analyzing the number of immunocompetent cells in blood.

## Claims

### Claim 1

A method for supplying immunodynamics-related information for use in determining therapy or prophylaxis for a disease and/or symptom of a subject comprising:
(i) calculating a discriminant score by assigning the cell-count of each of multiple types of immunocompetent cells in blood collected from the subject into a discriminant function;
(ii) determining a group into which the subject is to be sorted by the calculated discriminant score; and
(iii) displaying immunodynamics-related information of the determined group,
wherein;
the discriminant function is obtained by performing a discriminant analysis for a data cluster containing data of the condition of an individual and the cell-count of each of multiple types of immunocompetent cells in blood collected from the individual in a number that allows for the discriminant analysis, wherein the condition of the individual is set an objective variable and the multiple types of immunocompetent cells are set as explanatory variables; and
the group into which the subject is to be sorted is one of the multiple groups that are divided from the data cluster used for obtaining the discriminant function using discriminant scores as indicator.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the condition of an individual is selected from a group consisting of health, a disease, a disorder, a symptom or prognosis.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the immunodynamics-related information is obtained by:
(a) performing a multiple regression analysis for data of the cell-counts of n types of immunocompetent cells that constitute one group, wherein one type of immunocompetent cell among the n types of immunocompetent cells is set as an objective variable and n−1 types of immunocompetent cells excluding the one type of immunocompetent cell that is set as the objective variable are set as explanatory variables, and wherein n is an integer of 4 or more;
(b) ranking the n−1 types of immunocompetent cells in descending order according to the magnitude of the absolute value of the standard partial regression coefficient obtained from the multiple regression analysis;
(c) performing a regression analysis in which the one type of immunocompetent cell that is the objective variable in (a) above is set as an objective variable and the immunocompetent cell that is ranked as the first place in (b) above is set as explanatory variable, calculating the contribution ratio α1 which is considered as the influence degree of the first-place ranked immunocompetent cell β1; and
(d) performing a multiple regression analysis in which the one type of immunocompetent cell that is the objective variable in (a) above is set as an objective variable and m types of immunocompetent cells from the first to the m-th place ranked in (b) above are set as explanatory variables, calculating the contribution ratio αm, and calculating the influence degree βm of the immunocompetent cell ranked as m-th place by the following formula:
βm=αm−αm−1
for each of the immunocompetent cells ranked from the second to the m-th place; wherein m is more than 3 and up to n−1.

### Claim 4 (depends on 3)

The method according to claim 3, wherein the immunocompetent cells are three or more selected from a group consisting of: Th17+ lymphocyte, CD3-positive lymphocyte, CD4-positive lymphocyte, CD8-positive lymphocyte, CD20*DR lymphocyte, Th± lymphocyte, Th−2 lymphocyte, Th+2 lymphocyte, Act.Th1 lymphocyte, Act.Th2 lymphocyte, Ti*DR lymphocyte, Ti± lymphocyte, Ti−2 lymphocyte, Ti+2 lymphocyte, Tc*DR lymphocyte, Tc− lymphocyte, Tc+ lymphocyte, Ts*DR lymphocyte, Ts− lymphocyte, Ts+ lymphocyte, NK cell, NKT cell, N3+ cell, monocyte, basophil, eosinophil and neutrophil.

### Claim 5 (depends on 4)

The method according to claim 4, wherein the immunocompetent cells comprise Th17+ lymphocyte.

### Claim 6 (depends on 3)

The method according to claim 3, wherein the one type of immunocompetent cell that is set as the objective variable in (a) above is selected from a group consisting of: Tc*DR lymphocyte, CD20*DR lymphocyte, NK cell, NKT cell, basophil, eosinophil and neutrophil.

### Claim 7 (depends on 3)

A method of evaluating NK-cell activity using the influence degree according to claim 3 by the following formula:
NK-cell activity index={[monocyte influence degree (%) calculated using NK cell as an objective variable]×[Act.Th1 lymphocyte influence degree (%) calculated using NK cell as an objective variable]×[Tc*DR lymphocyte influence degree (%) calculated using NK cell as an objective variable]÷[the sum of the respective influence degrees (%) of all immunocompetent cells in which the influence degrees are calculated using NK cell as an objective variable]}×(the average number of NK cells per 1 μL blood of the data cluster);
provided that, in multiple regression analysis in which NK cell is set as the objective variable, the standard partial regression coefficients of monocyte, Act.Th1 lymphocyte and Tc*DR lymphocyte are all positive.

### Claim 8 (depends on 3)

A method of evaluating NK-cell ADCC (antibody-dependent cellular cytotoxicity) activity using the influence degree according to claim 3 by the following formula:
NK-cell ADCC activity index={[monocyte influence degree (%) calculated using NK cell as an objective variable]×[Act.Th2 lymphocyte influence degree (%) calculated using NK cell as an objective variable]×[CD20*DR lymphocyte influence degree (%) calculated using NK cell as an objective variable]÷[the sum of the respective influence degrees (%) of all immunocompetent cells in which the influence degrees are calculated using NK cell as an objective variable]}×(the average number of NK cells per 1 μL blood of the data cluster);
provided that, in multiple regression analysis in which NK cell is set as the objective variable, the standard partial regression coefficients of monocyte, Act.Th2 lymphocyte and CD20*DR lymphocyte are all positive.

### Claim 9 (depends on 3)

A method of evaluating NKT-cell activity using the influence degree according to claim 3 by the following formula:
NKT-cell activity index={[monocyte influence degree (%) calculated using NKT cell as the objective variable]×[Act.Th1 lymphocyte influence degree (%) calculated using NKT cell as the objective variable]×[Tc*DR lymphocyte influence degree (%) calculated using NKT cell as the objective variable]÷[the sum of the respective influence degrees (%) of all immunocompetent cells in which the influence degrees are calculated using NKT cell as the objective variable]}×(the average number of NKT cells per 1 μL blood of the data cluster);
provided that, in multiple regression analysis in which NKT cell is set as the objective variable, the standard partial regression coefficients of monocyte, Act.Th1 lymphocyte and Tc*DR lymphocyte are all positive.

### Claim 10 (depends on 3)

A method of evaluating NKT-cell ADCC (antibody-dependent cellular cytotoxicity) activity using the influence degree according to claim 3 by the following formula:
NKT-cell ADCC activity index={[monocyte influence degree (%) calculated using NKT cell as the objective variable]×[Act.Th2 lymphocyte influence degree (%) calculated using NKT cell as the objective variable]×[CD20*DR lymphocyte influence degree (%) calculated using NKT cell as the objective variable]÷[the sum of the respective influence degrees (%) of all immunocompetent cells in which the influence degrees are calculated using NKT cell as an objective variable]}×(the average number of NKT cells per 1 μL blood of the data cluster);
provided that, in multiple regression analysis in which NKT cell is set as the objective variable, the standard partial regression coefficients of monocyte, Act.Th2 lymphocyte and CD20*DR lymphocyte are all positive.

### Claim 11 (depends on 3)

A method of evaluating killer T-cell activity using the influence degree according to claim 3 by the following formula:
killer T-cell activity index={[monocyte influence degree (%) calculated using Tc*DR lymphocyte as the objective variable]×[Act.Th1 lymphocyte influence degree (%) calculated using Tc*DR lymphocyte as the objective variable]÷[the sum of the respective influence degrees (%) of all immunocompetent cells in which the influence degrees are calculated using Tc*DR lymphocyte as the objective variable]}×(the average number of Tc*DR lymphocytes per 1 μL blood of data cluster);
provided that, in multiple regression analysis in which Tc*DR lymphocyte is set as the objective variable, the standard partial regression coefficients of monocyte and Act.Th1 lymphocyte are both positive.

### Claim 12 (depends on 3)

A method of evaluating killer T-cell ADCC (antibody-dependent cellular cytotoxicity) activity using the influence degree according to claim 3 by the following formula:
killer T-cell ADCC activity index={[monocyte influence degree (%) calculated using Tc*DR lymphocyte as the objective variable]×[Act.Th2 lymphocyte influence degree (%) calculated using Tc*DR lymphocyte as the objective variable]×[CD20*DR influence degree (%) calculated using Tc*DR lymphocyte as the objective variable]÷[the sum of the respective influence degrees (%) of all immunocompetent cells in which the influence degrees are calculated using Tc*DR lymphocyte as the objective variable]}×(the average number of Tc*DR lymphocytes per 1 μL blood of data cluster)
provided that, in multiple regression analysis in which Tc*DR lymphocyte is set as the objective variable, the standard partial regression coefficients of monocyte, Act.Th2 lymphocyte and CD20*DR lymphocyte are all positive.

### Claim at position 13

13-14. (canceled)
